Moolec Secures Nasdaq Panel Support to Regain Listing Compliance
GEORGE TOWN, CAYMAN ISLANDS | January 26, 2026 — Moolec Science S.A. announced that Nasdaq Staff has issued a...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
GEORGE TOWN, CAYMAN ISLANDS | January 26, 2026 — Moolec Science S.A. announced that Nasdaq Staff has issued a...
HANGZHOU, China | December 24, 2025 — WORK Medical Technology Group LTD, a China-based supplier of Class I and...
